UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25 SEC FILE NUMBER
333-33662
NOTIFICATION OF LATE FILING ---------------
CUSIP NUMBER
---------------
(Check One): |X|Form 10-K |_|Form 20-F |_|Form 11-K |_|Form 10-Q |_|Form N-SAR
For Period Ended: March 31, 2000
( ) Transition Report on Form 10-K
( ) Transition Report on Form 20-F
( ) Transition Report on Form 11-K
( ) Transition Report on Form 10-Q
( ) Transition Report on Form N-SAR
For the Transition Period Ended:
-------------------------------------------
NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS
VERIFIED ANY INFORMATION CONTAINED HEREIN.
---------------------------------------------------------------------------
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
---------------------------------------------------------------------------
PART I -- REGISTRANT INFORMATION
---------------------------------------------------------------------------
Full Name of Registrants: Molecular Diagnostics & Therapeutics, Inc.
Former Name if Applicable
1880 Industrial Circle, Suite B-3
---------------------------------------------------------------------------
Address of Principal Executive Offices (Street and Number)
Longmont, CO 80501
---------------------------------------------------------------------------
City, State and Zip Code
--------------------------------------------------------------------------------
PART II - RULES 12b-25(b) AND (c)
--------------------------------------------------------------------------------
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed (Check box if appropriate)
_
|X| (a) The reasons described in reasonable detail in Part III
of this form could not be eliminated without
_ unreasonable effort or expense;
|X| (b) The subject quarterly report on Form 10-Q will be filed
on or before the fifth calendar day following the
_ prescribed due date; and
|_| (c) The accountant's statement or other exhibit required by
Rule 12(b)-25(c) has been attached if applicable.
--------------------------------------------------------------------------------
<PAGE>
PART III -- NARRATIVE
--------------------------------------------------------------------------------
State below in reasonable detail the reasons why the Form 10-Q could not be
filed within the prescribed time period. (Attach Extra Sheets If Needed)
Registrant is in the final stages of concluding negotiations for
interim financing. All of the Registrant's efforts have been directed
toward concluding these negotiations prior to the filing of its Form
10-K. It is expected that these negotiations will be completed and the
Registrant's Form 10-K will be filed within fifteen calendar days.
--------------------------------------------------------------------------------
PART IV --OTHER INFORMATION
--------------------------------------------------------------------------------
(1) Name and telephone number of person to contact in regard to this
notification:
Malcolm H. Benedict 303 485-8500
---------------------------------------------------------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months (or for such shorter) period that
the registrant was required to file such reports) been filed? If answer is
no, identify report(s). _ _
|X| Yes |_| No
---------------------------------------------------------------------------
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof? _ _
|_| Yes |X| No
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
Molecular Diagnostics & Therapeutics, Inc.
--------------------------------------------
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on their behalf by the undersigned
hereunto duly authorized.
Date June 29, 2000 By /s/ Malcolm H. Benedict
--------------------------- ---------------------------------------
Malcolm H. Benedict
